Circulation Reports
Online ISSN : 2434-0790
Rapid Communications
Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction
Yukihito Sato, Takashi Kuragaichi, Shunsuke Saga, Hiroyuki Nakayama, Tomoe Obata, Mitsumasa Watanabe, Kie Fujikura, Masatoki Watanabe, Ken-ichiro Hata, Hajime Ohgushi
Author information
Keywords: Heart failure, Mesenchymal cell, Regeneration therapy
JOURNAL OPEN ACCESS FULL-TEXT HTML

2021 Volume 3 Issue 9 Pages 550-554

Browse “Advance online publication” version
Details
Full-text HTML Download PDF (682K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Background:Although intracardiac injection or intracoronary delivery of mesenchymal stem cells (MSCs) has been reported, there have been few studies on the intravenous injection of MSCs, particularly in Japan.

Methods and Results:Five patients with left ventricular ejection fraction (LVEF) ≤45% received 1.0×108MSCs intravenously. The procedure did not induce significant changes in vital signs. One patient had an elevated body temperature after 1 day, but recovered spontaneously. Laboratory tests remained normal for 1 month after cell delivery. Computed tomography was performed after 1–2 years, and there was no evidence of malignancy.

Conclusions:In this pilot study of patients with reduced LVEF, intravenous MSC delivery had no adverse effects.

Content from these authors
© 2021, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
Favorites & Alerts

Recently viewed articles
Related journals
Circulation Journal
Share this page
feedback
 Top